TheraRadar
← Back
Data updated: Jun 28, 2026

EVITA SOLUTIONS

Generics

EVITA SOLUTIONS is a generic drug manufacturer focused on Metabolic.

2025
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

EVITA SOLUTIONS's Key Drugs

EVITA SOLUTIONS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

EVITA SOLUTIONS's Recent FDA Approvals

New NDA/BLA approvals for EVITA SOLUTIONS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

EVITA SOLUTIONS's Therapeutic Areas

EVITA SOLUTIONS's approved drugs and pipeline span 1 therapeutic area, led by Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 100%
1 drugs

EVITA SOLUTIONS's Top Competitors

EVITA SOLUTIONS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

EVITA SOLUTIONS Pipeline Snapshot

Active clinical trials for EVITA SOLUTIONS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Metabolic pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling